A Phase 1 Study of LY2940680 in Japanese Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs Taladegib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly; Eli Lilly and Company
- 30 Oct 2018 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 17 Feb 2018 Results (n=19) assessing safety, tolerability and pharmacokinetics of LY 2940680 in Japanese patients with advanced solid tumours, were published in the Investigational New Drugs.